Monitoring, Immunologic

• 

  Subject Areas on Research

  • 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA. 
  • Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. 
  • Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. 
  • Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays. 
  • Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. 
  • Development of tolerogenic strategies in the clinic. 
  • Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 
  • Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. 
  • Immune monitoring. 
  • Immune profiling: molecular monitoring in renal transplantation. 
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. 
  • Implementation of Good Clinical Laboratory Practice (GCLP) guidelines within the External Quality Assurance Program Oversight Laboratory (EQAPOL). 
  • Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies. 
  • Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. 
  • Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. 
  • Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. 
  • Premature translational termination products are rapidly degraded substrates for MHC class I presentation. 
  • Proteomics for monitoring immune responses to cancer vaccines. 
  • Quantitating cellular immune responses to cancer vaccines. 
  • Setting objective thresholds for rare event detection in flow cytometry. 
  • Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry. 
  • Surrogate markers of response to cancer immunotherapy. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. 
  • The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay. 
  • The Immunology Quality Assessment Proficiency Testing Program for CD3⁺4⁺ and CD3⁺8⁺ lymphocyte subsets: a ten year review via longitudinal mixed effects modeling. 
  • The eye: A window to the soul of the immune system. 
  • The role of quantitative PCR for the immune monitoring of cancer patients. 
  • Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays. 
  • Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.